Moderna Stock Piotroski F Score
| MRNA Stock | USD 107.89 3.43 3.28% |
Moderna | Piotroski F Score |
At this time, it appears that Moderna's Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
6.0
Piotroski F Score - Unavailable
| Current Return On Assets | Negative |
| Change in Return on Assets | Increased |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | Decrease |
| Current Ratio Change | Increase |
| Long Term Debt Over Assets Change | Lower Leverage |
| Change In Outstending Shares | Decrease |
| Change in Gross Margin | Increase |
Moderna Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Moderna is to make sure Moderna is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Moderna's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Moderna's financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.22 | 0.3665 |
|
| |||||
| Total Current Liabilities | 2.4 B | 3 B |
|
| |||||
| Non Current Liabilities Total | 868 M | 1.6 B |
|
| |||||
| Total Assets | 19.3 B | 18.4 B |
|
| |||||
| Total Current Assets | 5.8 B | 10.3 B |
|
|
Moderna F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Moderna's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Moderna in a much-optimized way.
Click cells to compare fundamentals
About Moderna Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
Moderna Current Valuation Drivers
We derive many important indicators used in calculating different scores of Moderna from analyzing Moderna's financial statements. These drivers represent accounts that assess Moderna's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moderna's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 6.9B | 613.7M | 6.4B | 37.4B | 33.7B | 35.4B |
About Moderna Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Moderna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moderna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moderna based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Moderna Altman Z Score, Moderna Correlation, Moderna Valuation, as well as analyze Moderna Alpha and Beta and Moderna Hype Analysis. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (12.33) | Revenue Per Share 17.927 | Quarterly Revenue Growth (0.45) | Return On Assets (0.12) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.